Alto Neuroscience’s (ANRO) Buy Rating Reiterated at BTIG Research

Alto Neuroscience (NYSE:ANRO)‘s stock had its “buy” rating reissued by analysts at BTIG Research in a note issued to investors on Wednesday, Benzinga reports. They presently have a $37.00 target price on the stock. BTIG Research‘s target price points to a potential upside of 24.63% from the company’s current price.

Other equities analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Alto Neuroscience in a research note on Tuesday, October 27th. Zacks Research upgraded shares of Alto Neuroscience from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 20th. Wedbush raised their target price on shares of Alto Neuroscience from $24.00 to $26.00 and gave the stock a “neutral” rating in a research note on Thursday, August 13th. Wall Street Zen downgraded shares of Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, September 12th. Finally, HC Wainwright lifted their target price on shares of Alto Neuroscience from $55.00 to $60.00 and gave the company a “buy” rating in a report on Monday, October 19th. Eight research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $37.88.

Alto Neuroscience Stock Performance

Shares of ANRO stock traded up $1.08 during midday trading on Wednesday, hitting $29.69. The company had a trading volume of 249,454 shares, compared to its average volume of 429,271. The stock has a market cap of $1.16 billion, a price-to-earnings ratio of -12.29 and a beta of 1.42. The company has a debt-to-equity ratio of 0.07, a current ratio of 14.85 and a quick ratio of 14.85. The company’s 50 day simple moving average is $26.71 and its 200 day simple moving average is $24.43. Alto Neuroscience has a 52-week low of $10.80 and a 52-week high of $37.48.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Tuesday, November 10th. The company reported ($0.54) EPS for the quarter, topping the consensus estimate of ($0.67) by $0.13. Research analysts anticipate that Alto Neuroscience will post -2.69 earnings per share for the current fiscal year.

Insider Activity at Alto Neuroscience

In related news, CFO Nicholas Smith sold 24,056 shares of Alto Neuroscience stock in a transaction that occurred on Wednesday, September 30th. The stock was sold at an average price of $25.82, for a total value of $621,125.92. Following the sale, the chief financial officer directly owned 24,060 shares in the company, valued at $621,229.20. The trade was a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 11.25% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the business. Alps Advisors Inc. lifted its holdings in Alto Neuroscience by 45.9% in the third quarter. Alps Advisors Inc. now owns 51,971 shares of the company’s stock valued at $1,327,000 after acquiring an additional 16,358 shares during the period. Profund Advisors LLC increased its holdings in shares of Alto Neuroscience by 379.1% in the 3rd quarter. Profund Advisors LLC now owns 37,885 shares of the company’s stock valued at $967,000 after purchasing an additional 29,977 shares in the last quarter. Sterling Capital Management LLC increased its holdings in shares of Alto Neuroscience by 1,045.7% in the 3rd quarter. Sterling Capital Management LLC now owns 1,054 shares of the company’s stock valued at $27,000 after purchasing an additional 962 shares in the last quarter. Farther Finance Advisors LLC lifted its stake in shares of Alto Neuroscience by 48,581.8% in the third quarter. Farther Finance Advisors LLC now owns 5,355 shares of the company’s stock valued at $137,000 after purchasing an additional 5,344 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Alto Neuroscience by 18.6% in the second quarter. Wellington Management Group LLP now owns 70,913 shares of the company’s stock valued at $1,871,000 after purchasing an additional 11,114 shares during the period.

About Alto Neuroscience

Alto Neuroscience is a clinical-stage biopharmaceutical company developing treatments for psychiatric and neurological conditions. The company uses neuroscience-based assessments, including brain activity and cognitive measures, to identify patient characteristics that may help guide treatment development and selection. Its investigational programs target conditions such as depression and other serious mental health disorders. Alto’s approach is intended to match treatments to biological or behavioral profiles rather than relying solely on diagnosis, with the goal of improving the development and use of therapies.